AU2006261852B2 - Purified component of blue-green algae and method of use - Google Patents

Purified component of blue-green algae and method of use Download PDF

Info

Publication number
AU2006261852B2
AU2006261852B2 AU2006261852A AU2006261852A AU2006261852B2 AU 2006261852 B2 AU2006261852 B2 AU 2006261852B2 AU 2006261852 A AU2006261852 A AU 2006261852A AU 2006261852 A AU2006261852 A AU 2006261852A AU 2006261852 B2 AU2006261852 B2 AU 2006261852B2
Authority
AU
Australia
Prior art keywords
selectin
extract
ligand
cells
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006261852A
Other languages
English (en)
Other versions
AU2006261852A1 (en
Inventor
Christian Drapeau
Gitte S. Jensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Desert Lake Technologies LLC
Original Assignee
Desert Lake Technologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Desert Lake Technologies LLC filed Critical Desert Lake Technologies LLC
Publication of AU2006261852A1 publication Critical patent/AU2006261852A1/en
Application granted granted Critical
Publication of AU2006261852B2 publication Critical patent/AU2006261852B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/748—Cyanobacteria, i.e. blue-green bacteria or blue-green algae, e.g. spirulina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
AU2006261852A 2005-06-24 2006-06-23 Purified component of blue-green algae and method of use Ceased AU2006261852B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US69380805P 2005-06-24 2005-06-24
US60/693,808 2005-06-24
US70088205P 2005-07-19 2005-07-19
US60/700,882 2005-07-19
PCT/US2006/024769 WO2007002570A1 (en) 2005-06-24 2006-06-23 Purified component of blue-green algae and method of use

Publications (2)

Publication Number Publication Date
AU2006261852A1 AU2006261852A1 (en) 2007-01-04
AU2006261852B2 true AU2006261852B2 (en) 2012-07-19

Family

ID=37188001

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006261852A Ceased AU2006261852B2 (en) 2005-06-24 2006-06-23 Purified component of blue-green algae and method of use

Country Status (12)

Country Link
US (3) US7651690B2 (cg-RX-API-DMAC10.html)
EP (1) EP1895973B1 (cg-RX-API-DMAC10.html)
JP (1) JP5006877B2 (cg-RX-API-DMAC10.html)
KR (1) KR101489728B1 (cg-RX-API-DMAC10.html)
AU (1) AU2006261852B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0612672B8 (cg-RX-API-DMAC10.html)
CA (1) CA2612694C (cg-RX-API-DMAC10.html)
ES (1) ES2546332T3 (cg-RX-API-DMAC10.html)
IL (1) IL188192A (cg-RX-API-DMAC10.html)
NZ (1) NZ565346A (cg-RX-API-DMAC10.html)
RU (1) RU2417093C2 (cg-RX-API-DMAC10.html)
WO (1) WO2007002570A1 (cg-RX-API-DMAC10.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6814961B1 (en) * 2001-05-14 2004-11-09 Gitte S. Jensen Method for enhancing stem cell trafficking
EP2026759B1 (en) * 2006-05-05 2015-07-08 Blaa Lonid Hf. Pharmaceutical and cosmetic use of extracts from algae obtainable from saline hot water sources
DK2046354T3 (da) * 2006-06-27 2011-10-31 Nutratec S R L Aphanizomenon Flos Aquae-fremstilling, ekstrakter og oprensede bestanddele deraf til behandling af neurologiske, neurodegenerative og humørforstyrrelser
AU2007264043B2 (en) * 2006-06-27 2012-03-15 Nutratec S.R.L. Extracts of Aphanizomenon Flos Aquae and nutritional, cosmetic and pharmaceutical compositions containing the same
US20080124318A1 (en) * 2006-11-28 2008-05-29 Jerold Lisson Algae supplement and treatment method
KR20100062140A (ko) * 2008-12-01 2010-06-10 부경대학교 산학협력단 푸코이단을 함유하는 골 형성 촉진 및 활성용 약학 조성물
US8563307B2 (en) 2009-02-24 2013-10-22 James Wang Treatment of immunosuppression-related disorders
US9370537B2 (en) * 2009-04-03 2016-06-21 Cerule, Llc Compositions and methods for reducing inflammation
IT1394412B1 (it) * 2009-06-05 2012-06-15 Eni Spa Procedimento per l'essiccazione di biomassa algale
US20140199380A1 (en) * 2010-05-11 2014-07-17 Benzion Geshuri Pharmaceutical composition comprising an algae adapted to increase the efficacy of an enzymatic inhibitor
BR112012033548A2 (pt) * 2010-06-28 2017-06-20 Stemtech Int Inc métodos e composições para melhorar a mobilização de células-tronco
US8679474B2 (en) 2010-08-04 2014-03-25 StemBios Technologies, Inc. Somatic stem cells
US8685845B2 (en) 2010-08-20 2014-04-01 International Business Machines Corporation Epitaxial growth of silicon doped with carbon and phosphorus using hydrogen carrier gas
TWI614340B (zh) 2011-09-28 2018-02-11 幹細胞生物科技股份有限公司 體幹細胞及其製備方法
WO2013074801A1 (en) 2011-11-18 2013-05-23 Stemtech International, Inc. Use of foti to enhance stem cell mobilization and proliferation
RU2015104535A (ru) * 2012-07-11 2016-08-27 Стемтек Интернэшнл, Инк. Композиции и способы для усиления мобилизации и пролиферации бластомероподобных стволовых клеток
CN104822827B (zh) 2012-12-06 2020-01-21 干细胞生物科技公司 Lgr5+体干细胞
EP2746769A1 (en) * 2012-12-21 2014-06-25 Stembios Technologies, Inc. Method for evaluating effect of action on subject based on stem celldynamics
US20150141901A1 (en) * 2013-11-08 2015-05-21 Alan S. Lichtbroun Low-level laser irradiation of stimulated human stem cells
RS59437B2 (sr) 2013-12-03 2025-01-31 Gerolymatos Int S A Jonske vodene kompozicije
CN107312063A (zh) * 2017-06-22 2017-11-03 乐清瑞耀食品技术有限公司 钝顶螺旋藻活性蛋白的制备方法
FR3087338B1 (fr) 2018-10-22 2020-10-09 Amadeite Extrait d'algues pour son utilisation pour le traitement ou la prevention de l'immunosuppression post-traumatique
US12188049B2 (en) * 2020-04-14 2025-01-07 Tzu Chi University Methods for mobilizing stem cells

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072769A2 (en) * 2000-03-27 2001-10-04 Genetics Institute, Llc Methods for purifying highly anionic proteins
WO2002004000A1 (en) * 2000-07-10 2002-01-17 The University Of Mississippi Potent immunostimulants from microalgae
WO2002044342A2 (en) * 2000-10-18 2002-06-06 The Brigham And Women's Hospital, Inc. Hematopoietic cell e-selection/l-selectin ligand polypeptides and methods of use thereof
US20040132105A1 (en) * 1991-02-05 2004-07-08 Cummings Richard D. Methods of detecting disorders involving defective p-selectin glycoprotein ligand or defective p-selectin
WO2004066969A2 (fr) * 2003-01-24 2004-08-12 Siricie Composition comprenant un extrait d'aphanizomenon flos-aquae, son utilisation et sa preparation
US6814961B1 (en) * 2001-05-14 2004-11-09 Gitte S. Jensen Method for enhancing stem cell trafficking

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5663911A (en) 1979-10-29 1981-05-30 Dainippon Ink & Chem Inc Cosmetic containing hard-soluble phycocyanin
JP2002069443A (ja) * 2000-08-30 2002-03-08 Microalgae Corporation 抗酸化剤及び該抗酸化剤を含有する化粧料

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132105A1 (en) * 1991-02-05 2004-07-08 Cummings Richard D. Methods of detecting disorders involving defective p-selectin glycoprotein ligand or defective p-selectin
WO2001072769A2 (en) * 2000-03-27 2001-10-04 Genetics Institute, Llc Methods for purifying highly anionic proteins
WO2002004000A1 (en) * 2000-07-10 2002-01-17 The University Of Mississippi Potent immunostimulants from microalgae
WO2002044342A2 (en) * 2000-10-18 2002-06-06 The Brigham And Women's Hospital, Inc. Hematopoietic cell e-selection/l-selectin ligand polypeptides and methods of use thereof
US6814961B1 (en) * 2001-05-14 2004-11-09 Gitte S. Jensen Method for enhancing stem cell trafficking
WO2004066969A2 (fr) * 2003-01-24 2004-08-12 Siricie Composition comprenant un extrait d'aphanizomenon flos-aquae, son utilisation et sa preparation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ASSREUY, A.M.S. et al. Mediators of Inflammation, 1997, vol. 6, pages 201-210 (A) *
BENEDETTI et al., Life Sciences, 2004, pages 2353-2362 *
KUMAR, K. et al., Indian Journal of Microbiology, 2003, Vol 43, No. 1, pages 9-16 (X) *

Also Published As

Publication number Publication date
JP5006877B2 (ja) 2012-08-22
CA2612694A1 (en) 2007-01-04
EP1895973A1 (en) 2008-03-12
US20070003647A1 (en) 2007-01-04
RU2008100847A (ru) 2009-07-27
US20100209461A1 (en) 2010-08-19
US7651690B2 (en) 2010-01-26
EP1895973B1 (en) 2015-08-19
NZ565346A (en) 2010-05-28
IL188192A (en) 2014-04-30
IL188192A0 (en) 2011-08-01
BRPI0612672B8 (pt) 2021-05-25
US7947284B2 (en) 2011-05-24
HK1114024A1 (zh) 2008-10-24
KR20080030047A (ko) 2008-04-03
CA2612694C (en) 2015-10-27
US20100092507A1 (en) 2010-04-15
WO2007002570A1 (en) 2007-01-04
RU2417093C2 (ru) 2011-04-27
BRPI0612672B1 (pt) 2018-12-11
BRPI0612672A2 (pt) 2010-11-30
KR101489728B1 (ko) 2015-02-04
JP2008546808A (ja) 2008-12-25
ES2546332T3 (es) 2015-09-22
AU2006261852A1 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
US7947284B2 (en) Purified component of blue-green algae and method of use
US8414881B2 (en) Method for enhancing stem cell trafficking
US20190276803A1 (en) Method of culturing immune cells, kit for thereof, immune cell cultured medium obtained by same method, cosmetic composition and pharmaceutical composition comprising thereof
Jensen et al. Mobilization of human CD34+ CD133+ and CD34+ CD133− stem cells in vivo by consumption of an extract from Aphanizomenon flos-aquae—related to modulation of CXCR4 expression by an L-selectin ligand?
Korpelainen et al. The receptor for interleukin 3 is selectively induced in human endothelial cells by tumor necrosis factor alpha and potentiates interleukin 8 secretion and neutrophil transmigration.
JP2016153430A (ja) 幹細胞の移動を増強するための方法および組成物
AU2013290276A1 (en) Compositions and methods for enhancing mobilization and proliferation of blastomere-like stem cells
US12178849B2 (en) Autoimmune disease treatment with chemokine-loaded alginate microparticles
HK1114024B (en) Purified extracts of blue-green algae and method of use
TW202245815A (zh) 源自馬奶酒之胞外體及其用途
US20100111905A1 (en) Methods for improved engraftment following stem cell transplantation
MX2007016597A (es) Componente purificado de algas azules-verdes y metodo de uso
JPWO2010008005A1 (ja) ストレスによって誘導される免疫機能変調改善剤
US20150359827A1 (en) Blue-green algae extract mixtures and methods of use
JP3970916B2 (ja) ナチュラルキラー細胞の増殖剤及び増殖方法
CN121646475A (zh) Nk细胞在制备治疗纤维化疾病的药物中的应用
Jensen et al. This article was originally printed in the Cardiovascular Revascularization Medicine Journal.
Schaeffer et al. related to modulation of CXCR4 expression by an L-selectin ligand?
TW201907926A (zh) 體幹細胞用於增加蛋白質精胺酸甲基轉移酶(prmt)位準的用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired